JP2005532350A5 - - Google Patents

Download PDF

Info

Publication number
JP2005532350A5
JP2005532350A5 JP2004509703A JP2004509703A JP2005532350A5 JP 2005532350 A5 JP2005532350 A5 JP 2005532350A5 JP 2004509703 A JP2004509703 A JP 2004509703A JP 2004509703 A JP2004509703 A JP 2004509703A JP 2005532350 A5 JP2005532350 A5 JP 2005532350A5
Authority
JP
Japan
Prior art keywords
etonogestrel
hrt
female
medicament
male
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004509703A
Other languages
English (en)
Japanese (ja)
Other versions
JP4716726B2 (ja
JP2005532350A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/050187 external-priority patent/WO2003102012A2/en
Publication of JP2005532350A publication Critical patent/JP2005532350A/ja
Publication of JP2005532350A5 publication Critical patent/JP2005532350A5/ja
Application granted granted Critical
Publication of JP4716726B2 publication Critical patent/JP4716726B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004509703A 2002-05-30 2003-05-22 新しいエトノゲストレルエステル Expired - Fee Related JP4716726B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02077119 2002-05-30
EP02077119.2 2002-05-30
PCT/EP2003/050187 WO2003102012A2 (en) 2002-05-30 2003-05-22 New etonogestrel esters

Publications (3)

Publication Number Publication Date
JP2005532350A JP2005532350A (ja) 2005-10-27
JP2005532350A5 true JP2005532350A5 (enExample) 2006-06-29
JP4716726B2 JP4716726B2 (ja) 2011-07-06

Family

ID=29595014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004509703A Expired - Fee Related JP4716726B2 (ja) 2002-05-30 2003-05-22 新しいエトノゲストレルエステル

Country Status (30)

Country Link
US (1) US7323454B2 (enExample)
EP (1) EP1513861B1 (enExample)
JP (1) JP4716726B2 (enExample)
KR (1) KR20050009723A (enExample)
CN (2) CN101100480A (enExample)
AR (1) AR040130A1 (enExample)
AT (1) ATE349458T1 (enExample)
AU (1) AU2003238081B2 (enExample)
BR (1) BR0311254A (enExample)
CA (1) CA2487722C (enExample)
CO (1) CO5631449A2 (enExample)
DE (1) DE60310714T2 (enExample)
DK (1) DK1513861T3 (enExample)
ES (1) ES2277085T3 (enExample)
HR (1) HRP20041101A2 (enExample)
IL (1) IL165087A0 (enExample)
IS (1) IS2421B (enExample)
MX (1) MXPA04011797A (enExample)
NO (1) NO20044898L (enExample)
NZ (1) NZ536619A (enExample)
PE (1) PE20040068A1 (enExample)
PL (1) PL373855A1 (enExample)
PT (1) PT1513861E (enExample)
RS (1) RS97604A (enExample)
RU (1) RU2325910C2 (enExample)
SI (1) SI1513861T1 (enExample)
TW (1) TW200403065A (enExample)
UA (1) UA80126C2 (enExample)
WO (1) WO2003102012A2 (enExample)
ZA (1) ZA200410410B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
EP1909973B1 (en) 2005-07-15 2018-08-22 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
SG192524A1 (en) 2008-04-17 2013-08-30 Micell Technologies Inc Stents having bioabsorbable layers
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
WO2010111232A2 (en) 2009-03-23 2010-09-30 Micell Technologies, Inc. Drug delivery medical device
CA2757276C (en) 2009-04-01 2017-06-06 Micell Technologies, Inc. Coated stents
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
WO2012009684A2 (en) 2010-07-16 2012-01-19 Micell Technologies, Inc. Drug delivery medical device
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN110269959A (zh) 2013-03-12 2019-09-24 脉胜医疗技术公司 可生物吸收的生物医学植入物
AU2014265460B2 (en) 2013-05-15 2018-10-18 Micell Technologies, Inc. Bioabsorbable biomedical implants
RU2595818C1 (ru) * 2015-05-25 2016-08-27 Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" Способ комплексного лечения дисфункции яичников при применении гормонального контрацептива имплантата "импланона"
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1013284B (de) 1956-03-22 1957-08-08 Schering Ag Verfahren zur Einfuehrung der Reste wenig reaktionsfaehiger Carbonsaeuren, insbesondere des ª‰-Cyclopentyl-propionylrestes, in die 17ª‡-staendige Oxygruppe solcher Steroide, die am Kohlenstoffatom 17 neben der Oxygruppe eine Acetylgruppe tragen
GB845442A (en) 1956-03-22 1960-08-24 Schering Ag Manufacture of steroid compounds
GB8313921D0 (en) * 1983-05-19 1983-06-22 World Health Org Contraceptive compositions
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
AU692504B2 (en) 1993-12-27 1998-06-11 Akzo Nobel N.V. Percutaneously absorbable preparation
WO1997003709A1 (de) * 1995-07-17 1997-02-06 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
DE19613698A1 (de) 1995-07-17 1997-01-23 Schering Ag Mittel zur transdermalen Applikation enthaltend Ester des 13-Ethyl-17ß-hydroxy-11-methylen-18,19-dinor-17alpha-pregn-4-en-20-yn-3-ons
DE19531936A1 (de) * 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
WO1999067271A1 (en) 1998-06-19 1999-12-29 Akzo Nobel N.V. Testosterone derivative
WO1999067270A1 (en) 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
US6180682B1 (en) 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters

Similar Documents

Publication Publication Date Title
JP2005532350A5 (enExample)
RU2004138807A (ru) Новые сложные эфиры этоногестрела
Tang et al. The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion
CA2420348A1 (en) Non-hormonal vaginal contraceptive
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
CA2467558A1 (en) Creation of tissue engineered female reproductive organs
JP2013018787A5 (enExample)
JP2005517669A5 (enExample)
WO2007129013A3 (en) Improvements in or relating to uterine manipulators
JP2013523693A5 (enExample)
NZ591627A (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Tang et al. Medical abortion in the second trimester
WO2008067458A3 (en) A kit for contraception and prevention of sexually transmitted infections
JP2005512561A5 (enExample)
CN209136812U (zh) 一种宫腔防粘连硅胶环
JP2005532336A5 (enExample)
Bygdeman Prostaglandin analogues and their uses
CA2623024A1 (en) Use of estradiol valerate or estradiol combined with dienogest for the oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives
Leader et al. Vaginally administered 16, 16-dimethyl-prostaglandin E2 as an agent for pre-operative cervical dilatation
CN2464285Y (zh) 全方位安全套
CN204106298U (zh) 新型加长避孕套
CN2513545Y (zh) 防性病避孕套
WO2006042561A2 (en) Intrauterine contraceptive system with copper and progesterone
WO2013017007A1 (zh) 一种节育器的支架
CN2391582Y (zh) 性病预防避孕套